Hederan filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

hederan filmom obložene tablete

belupo lijekovi i kozmetika d.d., ulica danica 5, koprivnica - Сухи ekstrakt bršljanovog lista (vrijeme helicis mjestu folii suhi ekstrakt) - filmom obložena tableta - 35 mg - urbroj: jedna filmom obložena tableta sadrži 35 mg ekstrakta (kao suhi ekstrakt) iz hedera helix l., folium (bršljanov list) (4-8 : 1); ekstrakcijsko otapalo: etanol 30% m/m.

Hederan sirup Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

hederan sirup

belupo lijekovi i kozmetika d.d., ulica danica 5, koprivnica, hrvatska - suhi ekstrakt bršljanovog lista (4-8 : 1), ekstrakcijsko otapalo: etanol 30 % (m/m) - sirup - 3,675 mg/ml - urbroj: 1 mililitar sirupa sadrži 3,675 mg ekstrakta (kao suhi ekstrakt) iz hedera helix l., folium (bršljanov list) (4–8 : 1); ekstrakcijsko otapalo: etanol 30% m/m

HERBIFIT HEDERIN sirup 20 mg/5 mL  40 mg/5 mL sirup Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

herbifit hederin sirup 20 mg/5 ml 40 mg/5 ml sirup

pharmamed d.o.o. travnik - Сухи ekstrakt list bršljena - sirup - 20 mg/5 ml 40 mg/5 ml - 100 g sirupa sadrži: 0,350,70 g suhog ekstrakta bršljana (hedera helix l., folium) (48 : 1), što odgovara 70 mg hederakozida c (ekstraciono sredstvo 30% m/m etanol)

Erivedge Europska Unija - hrvatski - EMA (European Medicines Agency)

erivedge

roche registration gmbh - vismodegib - karcinom, bazalna stanica - antineoplastična sredstva - erivedge indiciran za liječenje odraslih bolesnika s simptomatske метастатической базальноклеточной karcinom - местнораспространенного базально srpastih stanica karcinom neprikladne za kirurško liječenje ili radioterapije.

Libtayo Europska Unija - hrvatski - EMA (European Medicines Agency)

libtayo

regeneron ireland designated activity company (dac) - cemiplimab - karcinom, squamous cell - antineoplastična sredstva - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Odomzo Europska Unija - hrvatski - EMA (European Medicines Agency)

odomzo

sun pharmaceutical industries europe b.v. - sonidegib difosfat - karcinom, bazalna stanica - antineoplastična sredstva - odomzo je indiciran za liječenje odraslih bolesnika s lokalno uznapredovalim karcinom bazalnih stanica (bcc) koji nisu podvrgnuti kurativna operacija ili zračenje terapija.

Daurismo Europska Unija - hrvatski - EMA (European Medicines Agency)

daurismo

pfizer europe ma eeig - glasdegib maleate - leukemija, mieloidna, akutna - antineoplastična sredstva - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.

Ibutren Flu 200 mg/30 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

ibutren flu 200 mg/30 mg filmom obložene tablete

sandoz d.o.o., maksimirska 120, zagreb - ibuprofenum, pseudoephedrinum - filmom obložena tableta - 200 mg + 30 mg - urbroj: svaka filmom obložena tableta sadrži 200 mg ibuprofena i 30 mg pseudoefedrinklorida

Olytabs 200 mg/30 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

olytabs 200 mg/30 mg filmom obložene tablete

johnson & johnson s.e. d.o.o., oreškovićeva 6h, zagreb, hrvatska - ibuprofenum, pseudoephedrinum - filmom obložena tableta - 200 mg + 30 mg - urbroj: jedna filmom obložena tableta sadrži 200 mg ibuprofena i 30 mg pseudoefedrinklorida

Imbruvica Europska Unija - hrvatski - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.